Andrea Kreidenweiss

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri et al. · The Lancet Infectious Diseases · 2021 · 175 citations · Full text

Veterinary Medicine, Infectious Diseases, Molecular Virology +16

Immune response to SARS-CoV-2 variants of concern in vaccinated individuals

Matthias Becker, Alex Dulovic, Daniel Junker et al. · Nature Communications · 2021 · 162 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

Peter G. Kremsner, Philipp Mann, Arne Kroidl et al. · Wiener klinische Wochenschrift · 2021 · 132 citations · Full text

Veterinary Medicine, Immunology, Molecular Pharmaceutics +17

Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon

Andrea Kreidenweiss, Peter G. Kremsner, Benjamin Mordmüller · Malaria Journal · 2008 · 114 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +17

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Peter G. Kremsner, Philipp Mann, Jacobus J. Bosch et al. · medRxiv · 2020 · 103 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17